𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck

✍ Scribed by Anju Parthan; Marshall R. Posner; Caroline Brammer; Philippe Beltran; Jeroen P. Jansen

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
177 KB
Volume
31
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Trial TAX 324 showed that induction chemotherapy with docetaxel plus cisplatin and 5‐fluorouracil (TPF) compared with cisplatin and 5‐fluorouracil (PF) followed by chemoradiation increases survival and time to progression in squamous cell carcinoma of head and neck (SCCHN).

Methods

A Markov model was developed to estimate the cost‐effectiveness of induction chemotherapy with docetaxel in the United Kingdom from the payer perspective. Health states were based on the WHO criteria for objective response to cancer treatments. Efficacy and safety data were obtained from the trial. Resource utilization, costs, and utility data were primarily derived from the literature.

Results

A patient on TPF gained 4.1 quality adjusted life years (QALYs) versus 2.0 QALYs for PF patient. Corresponding lifetime costs were £32,440 and £28,718. The cost per QALY gained for TPF versus PF was £1782.

Conclusions

TPF is cost‐effective as induction chemotherapy in locally advanced SCCHN compared with PF. Local treatment patterns may impact findings for other countries. © 2009 Wiley Periodicals, Inc. Head Neck, 2009

📜 SIMILAR VOLUMES

Preoperative sequential chemotherapy in
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck
✍ Sandrine Faivre; Adina Marti; Olivier Rixe; François Janot; Morbize Julieron; Mi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB 👁 1 views

## Abstract ## Background. Induction chemotherapy may contribute to decreased local and distant recurrences in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) resectable for cure. ## Methods. Patients with previously untreated locally advanced stage III–IV (N0

Docetaxel, cisplatin, and 5-fluorouracil
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck : The Dana Farber Cancer Institute experience
✍ Robert Haddad; A. Dimitrios Colevas; Roy Tishler; Paul Busse; Laura Goguen; Chri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract ## BACKGROUND The authors conducted a series of four Phase I–II trials of high‐dose and intermediate‐dose docetaxel, cisplatin, and 5‐fluorouracil (TPF)‐based induction chemotherapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). The chemotherapy regime

Phase II study of induction chemotherapy
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck
✍ Dong M. Shin; Bonnie S. Glisson; Fadlo R. Khuri; Scott M. Lippman; Lawrence Gins 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 1 views

## Abstract ## BACKGROUND This Phase II trial was conducted to determine the response rate, particularly of the primary sites, tolerability, and toxicity of induction chemotherapy of paclitaxel, ifosfamide, and carboplatin for patients with previously untreated locally advanced squamous cell carci